Claims for Patent: 8,232,245

Summary for Patent: 8,232,245

Title:	Caspofungin formulations
Abstract:	The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. The compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. The compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product.
Inventor(s):	Welz; Christian (Brixlegg, AT), Stubauer; Gottfried (Innsbruck, AT), Schmarda; Andreas (Goetzens, AT), Jennewein; Herwig (Absam, AT), Macher; Ingolf (Woergl, AT), Ludescher; Johannes (Breitenbach, AT)
Assignee:	Sandoz AG (Basel, CH)
Application Number:	12/374,489
Patent Claims:	1. A pharmaceutical composition comprising: a pharmaceutically acceptable salt of caspofungin; and a pharmaceutically acceptable amount of an excipient effective to form a lyophilized cake, wherein said composition is substantially free of any additional pH modifier. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of caspofungin comprises an acid addition salt with an organic acid comprising at least one organic acid selected from the group consisting of acetic, citric, tartaric, propionic, succinic, oxalic, malic, maleic, lactic, glutamic, and pamoic acid. 3. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of caspofungin is caspofungin diacetate. 4. The pharmaceutical composition of claim 1, wherein the excipient comprises one or more bulking agents. 5. The pharmaceutical composition of claim 4, wherein the bulking agents comprise mannitol, sucrose or a combination thereof. 6. The pharmaceutical composition of claim 1, comprising a) about 0.1 mg/ml to about 500 mg/ml caspofungin calculated as caspofungin base, and b) about 10 mg/ml to about 200 mg/ml of the excipient, the excipient comprising at least one bulking agent, and water. 7. The pharmaceutical composition of claim 1, comprising a) about 42 mg/ml caspofungin calculated as caspofungin base, and b) about 50 mg/ml of the excipient comprising a mixture of about 20 mg/ml of mannitol and about 30 mg/ml of sucrose, and water. 8. The pharmaceutical composition of claim 1, wherein the composition has a pH value of about 5 to about 7. 9. A lyophilized powder formed from the pharmaceutical composition according to one of claims 2, 3, and 4-8 being suitable for reconstitution to form a liquid composition for parenteral administration, wherein the lyophilized powder is substantially free of any additional pH modifier. 10. A reconstituted pharmaceutical composition formed from the lyophilized powder according to claim 9 wherein the reconstituted pharmaceutical composition is substantially free of any additional pH modifier. 11. The reconstituted pharmaceutical composition of claim 10, wherein the composition has a pH value of about 5 to about 8. 12. A pharmaceutical composition of claim 1, which is a stable formulation. 13. The reconstituted pharmaceutical composition of claim 10, having less than 500 sub-visible particles per vial, the particles having a size greater than 10 .mu.m. 14. A method of using a pharmaceutical composition for the manufacture of a medicament for the prevention and/or treatment of fungal infections or conditions caused by Candida sp, and/or by Aspergillus sp, and/or by Pneumocystis jiroveci in a mammal, wherein the pharmaceutical composition comprises: a pharmaceutically acceptable salt of caspofungin; and a pharmaceutically acceptable amount of an excipient effective to form a lyophilized cake, wherein the composition is substantially free of any additional pH modifier, the method comprising forming the medicament from the pharmaceutical composition. 15. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable salt of caspofungin, which process comprises the steps of: 1) dissolving a bulking agent or a combination of bulking agents in water to form a solution; 2) adding a pharmaceutically acceptable salt of caspofungin to the solution and dissolving the salt of caspofungin in the solution; 3) filtering the solution obtained in step 2) to obtain a filtered solution; 4) freezing the filtered solution obtained in step 3) to form a frozen solution; and 5) freeze drying the frozen solution to form the pharmaceutical composition, wherein the composition is substantially free of any additional pH modifier. 16. The pharmaceutical composition of claim 1, comprising a) about 20 mg/ml to about 60 mg/ml caspofungin calculated as caspofungin base, and b) about 40 mg/ml to about 60 mg/ml of the excipient, the excipient comprising at least one bulking agent, and water. 17. The pharmaceutical composition of claim 1, wherein the composition has a pH value of about 5.5 to about 6.5. 18. The pharmaceutical composition of claim 1, wherein the composition has a pH value of about 6.0. 19. The reconstituted pharmaceutical composition of claim 10, wherein the aqueous solution comprises distilled or sterile water for injection. 20. The reconstituted pharmaceutical composition of claim 10, wherein the aqueous solution comprises bacteriostatic water for injection which optionally comprises methylparaben and/or propylparaben and/or 0.9% benzyl alcohol. 21. The reconstituted pharmaceutical composition of claim 10, wherein the aqueous solution comprises saline or physiological saline. 22. The reconstituted pharmaceutical composition of claim 21, wherein the saline comprises at least one of a 0.9% solution of sodium chloride, a 0.45% or a 0.225% solution of sodium chloride. 23. The reconstituted pharmaceutical composition of claim 10, wherein the composition has a pH value of about 6.0 to about 7.5. 24. The reconstituted pharmaceutical composition of claim 10, wherein the reconstituted pharmaceutical composition is injectable intravenously. 25. A method of treating a patient for a fungal infection comprising: reconstituting a pharmaceutical composition by combining a lyophilized powder according to claim 9 with an aqueous solution to form the reconstituted pharmaceutical composition that is free of visual particles; and injecting the reconstituted pharmaceutical composition intravenously into a patient.

Details for Patent 8,232,245

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2026-07-26